Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

We explored the association of early tumor shrinkage (ETS) and non‐ETS with efficacy of first‐line and consecutive second‐line treatment in patients with KRAS wild‐type metastatic colorectal cancer treated in FIRE‐3. Assessment of tumor shrinkage was based on the sum of longest diameters of target l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2017-04, Vol.140 (8), p.1918-1925
Hauptverfasser:	Modest, Dominik P., Stintzing, Sebastian, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kiani, Alexander, Vehling‐Kaiser, Ursula, Al‐Batran, Salah‐Eddin, Heintges, Tobias, Lerchenmüller, Christian, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Scheithauer, Werner, Kirchner, Thomas, Jung, Andreas, Stauch, Martina, von Einem, Jobst Christian, Moehler, Markus, Held, Swantje, Heinemann, Volker
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage bevacizumab Bevacizumab - administration & dosage Camptothecin - administration & dosage Camptothecin - analogs & derivatives Cancer cetuximab Cetuximab - administration & dosage Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Disease-Free Survival early tumor shrinkage Female Fluorouracil - administration & dosage Humans Immunotherapy Kaplan-Meier Estimate KRAS Leucovorin - administration & dosage Male Medical research Metastases Metastasis Middle Aged Monoclonal antibodies Proto-Oncogene Proteins p21(ras) - genetics RAS Remission Induction sequence Shrinkage Survival Targeted cancer therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We explored the association of early tumor shrinkage (ETS) and non‐ETS with efficacy of first‐line and consecutive second‐line treatment in patients with KRAS wild‐type metastatic colorectal cancer treated in FIRE‐3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to 0 to
ISSN:	0020-7136 1097-0215
DOI:	10.1002/ijc.30592